Home / Market News / $CLDX
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Canaccord Genuity Raises Price Target for Celldex Therapeutics

Nov 6, 2026, 11:06 PM UTC · Primary ticker $CLDX

Canaccord Genuity has increased its price target for Celldex Therapeutics from $60 to $68. This analyst upgrade suggests a more optimistic valuation of the company, which could positively influence investor sentiment and stock performance in the short term.

Canaccord Genuity, a prominent financial services firm, has raised its price target for Celldex Therapeutics (CLDX) from $60 to $68. This action indicates that the analyst firm has a more favorable outlook on the company's future prospects and valuation. This news is primarily positive for current and potential investors in Celldex Therapeutics, as it signals a potential upside for the stock. In the short term, this upgrade could lead to increased buying interest and a bump in the stock price. Long-term implications depend on whether the company's fundamentals align with this revised valuation, offering an opportunity for traders to capitalize on potential upward momentum.

$CLDX positive Price target increase
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.